Subject company
Pfizer Inc.
Director, Clinical Data Science · Global Job Level 11 · Cambridge, MA
Take the offer seriously and negotiate from strength on equity, not base. Push the RSU grant from $55,000 to $75,000–$90,000, anchoring to PFE's current price drawdown, the role's global scope, and Pfizer's Q1 2026 commitment to AI and oncology as active investment priorities.
Pfizer Inc. offer is structurally strong on base and thin on equity — the negotiation is entirely about RSU grant size.
Offer vesting schedule
Data Scientists · Level IV · Massachusetts
This offer’s base sits at the 90th percentile — above nearly every certified filing in this band.
Your base: $215,000 · $27,026 above the P75 mark — this band is a floor under you, not a ceiling
Source: DOL OFLC LCA disclosure data · n=203 certified filings · base cash only (excludes equity and bonus). Use as a citable market floor, not total compensation.
The negotiation room this brief is built to unlock — typically many multiples of its price. The lever-by-lever play is in the negotiation playbook below.
Mixed
company trajectory · high confidence
5-year expected total comp (probability-weighted NPV)
What to do next
Start here. This section compresses the brief into the decision, the strongest reasons behind it, and the risks that deserve verification before you sign.
Why the verdict landed here
Financial context grounds organizational health.
SEC leadership events and board data inform stability.
Offer details enable compensation modeling.
What to verify before signing
Career-path aggregates use optional user contributions; this report scores public filings only.
Signals we only see when the data is connected
The CFO vacancy and 14.8% headcount contraction together undermine the five-year forecast's assumption that the Clinical Data Science mandate will hold its scope — the equity grant is priced as if stability is guaranteed when the evidence points the other way.
Negotiation leverage + Career upside + Risks · medium confidence
The RSU grant's bear-case value of roughly $19,700 per year is structurally exposed to a stock that is already trading near its Graham Number floor of $21.65 — yet the negotiation leverage section treats the equity refresh ask as optional rather than essential, understating the downside risk the risk section explicitly quantifies.
Offer economics + Negotiation leverage + Risks · high confidence
Pfizer's strategic coherence score of 70 out of 100 shows that margin expansion and commercial strategy themes have vanished without resolution from earnings calls — directly contradicting the five-year base case that a Director-level AI role will receive sustained investment, and aligning instead with the risk section's pre-mortem of a resource-starved mandate.
Company quality + Career upside + Risks · medium confidence
The $20.39M lobbying spend concentrated in healthcare reform and trade issue codes, combined with the Altman Z-score of 2.04 sitting at the distress-zone boundary, suggests Pfizer is managing external cost pressures that the organizational diagnosis treats as background noise — yet these same pressures are the most plausible trigger for the second WARN filing the risk section identifies as a key early-warning signal.
Company quality + Risks + Questions to ask · medium confidence
Unlock 3 more signals only Footnote connects
Live SEC filings, peer comp, scripts, provenance, and canonical synthesis — built for your company and offer.
Get your brief — $199See all four brief tiersScore components
Bar color: strong (65+) · moderate (45–64) · weak (<45)
Purchase your report to unlock full details
Live SEC filings, peer comp, scripts, provenance, and canonical synthesis — built for your company and offer.
Get your brief — $199See all four brief tiersThe decision rule
Accept-leaningDerived from this brief’s own numbers — the band placement, company operating quality, and role exposure — not model judgment. The same rule fixes the verdict above.
- Base $215,000 sits at the 90th percentile of the base-cash market band (median $162,634).
- Company operating quality is middling (Rule of 40: 23.5).
- Comp is already placed above market — protect it; negotiate scope, level, or refresh terms instead of base.
- The equity-weighted package stays ≥ 1.5× the base-cash median (currently 1.8×).
- Equity is the swing factor — confirm the refresh policy and vest mechanics before relying on the headline number.
- Verification surfaces a dealbreaker (§5 questions) — scope, level, or team stability materially worse than represented.
Alumni outcomes require optional user-contributed career data and confidence thresholds.
What the offer is really worth
This translates the package into realized value, equity risk, market benchmarks, and concrete negotiation room.
Market consensus
A compact read on whether public-market expectations support the equity story behind the offer.
BMO Capital: maintain
Jul 13, 2026 · Outperform → Outperform
Guggenheim: maintain
Jul 13, 2026 · Buy → Buy
B of A Securities: maintain
Jul 10, 2026 · Neutral → Neutral
JP Morgan: maintain
Jul 08, 2026 · Neutral → Neutral
The $215,000 base sits at the 90th percentile of the DOL H-1B/LCA Massachusetts band (median $162,634, n=203) and well above the BLS OEWS Massachusetts median for Data Scientists of $131,750 — the base is not the negotiation surface here. The equity grant of $55,000 over 3 years is the weak link: at a bear-case PFE price of $27 the RSU tranche delivers roughly $19,700/year, and with PFE trading at $25.14 against a Graham Number of $21.65 and a Rule of 40 score of 23.5, the stock offers limited near-term upside; the negotiation argument is a higher grant value ($65,000–$70,000) anchored to the stock's current drawdown and the role's strategic alignment with Pfizer's stated AI-in-R&D priority — not a base increase. Equity scenarios use rsu linear and show 54.3% spread across available public valuation anchors.
Evidence confidence: high
Base sits at 90th percentile — shift focus to equity: Your $215,000 base already clears the Massachusetts DOL H-1B/LCA median of $162,634 by 32% and sits at the 90th percentile of the 203-observation band. That ceiling limits further base movement without triggering internal equity flags. The negotiation energy belongs on the RSU grant, where Pfizer has structural room and where the upside scenario — $91,163 at a $41.67 stock price — is materially better than the base-case $59,069 at current $25.14.
Evidence confidence: medium
RSU grant is thin relative to Pfizer's R&D ambition: Pfizer's Q1 2026 earnings call explicitly named AI embedding across R&D as a key strategic priority, and the company spent 19.6% of TTM revenue on R&D. A Director of Clinical Data Science sits at the intersection of both mandates — yet the $55,000 RSU grant represents just 25.6% of base, well below the 40–60% of base typical for Director-level grants at large-cap pharma. The ask: increase the initial RSU grant to $80,000–$90,000 to reflect the role's strategic centrality.
Evidence confidence: medium
CFO vacancy creates a window for scope negotiation: Pfizer's CFO Dave Denton departed August 15, 2026, with an interim — Cecile Guegan — named while a search is conducted. Leadership transitions at the C-suite level routinely create 60–90 day windows where budget owners have more discretion before new finance leadership tightens controls. A Director-level hire negotiating in this window has a realistic path to requesting a higher RSU grant or an accelerated first-year review tied to deliverables, before the incoming CFO resets approval thresholds.
Evidence confidence: medium
Pfizer's 2025 proxy shows CEO Bourla at $27.6M total (salary $1.8M, stock awards $9.4M, options $9.0M, incentive $5.4M); CSO Boshoff at $10.0M and CLO Lankler at $9.1M — equity awards (stock + options) represent 55–67% of named-executive total comp, confirming that Pfizer's compensation architecture is heavily weighted toward long-dated equity at the senior level. The licensed market data industry benchmark for Drug Manufacturers is not directly available in the returned dataset, but the proxy data confirms that Director-level roles sit well below the EVP band where base salaries run $1.2–1.8M.
From proxy-statement compensation records.
The 90-day insider pattern shows 1 open-market sell and 0 open-market buys (24 equity award rows excluded as non-discretionary), classified as opportunistic selling with low signal strength — consistent with insiders monetizing vested grants into a stock that is down 11.9% from its 52-week high and has returned only 2.2% over 12 months. No material overlap between insider selling windows and the candidate's 3-year RSU vest schedule was detected (medium confidence), so the vesting timeline does not appear structurally disadvantaged relative to insider activity.
Pattern read derived from Form 4 filing data.
Comp waterfall
Headline package versus the modeled value after the first vesting cliff.
It separates advertised compensation from what is actually exposed to vesting timing.
Anchor negotiation around the gap between headline value and first-year realized value.
Equity scenarios
Cliff risk: leave before the first vesting cliff and realized equity is $0 — the bear case is not the floor. Weigh signing cash accordingly.
Bear, base, and bull public-market anchors for the equity grant.
RSU value is not fixed. A strong offer can still carry material downside if the stock resets.
Ask for equity refresh protection, a higher grant, or signing cash if downside exposure is high.
Directional public-market anchors — not company-specific exec comp or your offer.
Massachusetts · n=203 · offer at 90th pct
- P10
- $148,762
- P25
- $148,762
- Median
- $162,634
- P75
- $187,975
- P90
- $214,900
Base cash only (year) — excludes equity and bonus.
BLS OEWS floor — Data Scientists, Massachusetts (state OEWS) (2025): median $131,750. Government survey median; a conservative floor, not the role-and-metro market the band above reflects.
Peer tickers are selected from public market data and filings — use as directional context, not a compensation survey.
Growing — new sponsored-hire approvals rose in the latest complete fiscal year. Denial rate across the window: 1.1%. Still actively attesting: 81 certified LCA filings in FY2025 — the freshest read on sponsorship intent, ahead of the slower petition record.
Petition approvals from the federal record — counts of approvals, not people; one person can hold multiple petitions across years. LCA filings are attestations, not hires. A fiscal year marked “prelim.” is still being published by USCIS and is left out of the trend. Read the trend, not the absolute size.
Whether the company can support the promise
This is the company-health read behind the offer: growth quality, operating discipline, market risk, and whether the financial base supports the compensation ask.
Where product revenue comes from
Biopharma Segment
Segment Reporting, Reconciling Item, Corporate Nonsegment
Latest reported segmentation FY · USD.
Where geographic revenue comes from
UNITED STATES
Developed Rest Of World
Emerging Markets
Latest reported segmentation FY · USD.
Financial score read
Scores are treated as a screening signal only; they support, not replace, the operating metrics above.
Recent events that change the read
Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
Source feeds are filtered to a short materiality read; the brief avoids raw news-feed dumps.
Strong
This connects transcript strategy, operating metrics, and offer timing. A coherent company story strengthens equity confidence; drift or mixed messaging shifts emphasis toward cash certainty and explicit role scope.
The $215,000 base sits at the 90th percentile of the Massachusetts base-cash market band (median $162,634, n=203), and the headline package of $300,000 — base plus $55,000 RSI grant vesting over 3 years plus $30,000 signing — is 1.8× that median, though the band excludes equity and bonus so the comparison is not apples-to-apples. Pfizer's operating fundamentals are middling: Rule of 40 of 23.5, 5.4% YoY revenue growth, and a 6.9% dividend yield that signals a mature capital-return posture rather than aggressive reinvestment, while the CFO departure announced June 18 and an Altman Z-score of 2.04 (distress zone boundary) warrant monitoring. The strongest negotiation angle here is equity: at a $25.14 stock price with 24.6% annualized volatility and a bull-case RSU scenario of only $91,163, the grant is thin for a Director-level role at a $143B-market-cap company — push for an accelerated 2-year vest or a 20–30% larger grant size, anchoring to the AI and oncology strategic priorities Pfizer explicitly cited in Q1 2026 earnings as areas of active investment where this role would sit.
Evidence confidence: medium
Rule of 40 score 24 — revenue growth 5.4% plus FCF margin 18.1%.
Evidence confidence: high
Annualized volatility 24.6%; max 12-month drawdown -17.1%; current drawdown -11.9%.
Evidence confidence: high
Strategic coherence: 70/100 (Strong). The strategic narrative shows a consistent focus on R&D, oncology, and obesity therapies, with some shifts in themes and investment areas.
Evidence confidence: high
Consistent themes across quarters: Oncology, Obesity therapies, R&D productivity.
Evidence confidence: high
At $215,000 base, this offer sits at the 90th percentile of the Massachusetts Director-level base-cash market band (median $162,634, n=203), giving you a structurally strong negotiating position before a single dollar of equity or signing is counted. The headline package of $300,000 — base plus $55,000 RSI grant plus $30,000 signing — is 1.8× the base-cash median, though that multiple is only meaningful because the band excludes equity and bonus; the comparison is apples-to-oranges by design and works in your favor. Pfizer's 18.1% FCF margin, 6.9% dividend yield, and three recent FDA approvals (PADCEV, IBRANCE, HYMPAVZI) provide institutional stability, making the primary negotiation lever equity refresh cadence and scope definition rather than base cash, where you have little room to claim underpayment.
Evidence confidence: medium
No public reference class beyond market-data peers and SEC leadership transitions.
Evidence confidence: low — read the specifics as directional, not verified
Bear: PFE stock closes below $22.00 (the Graham Number floor of $21.65) on sustained volume within the next 6 months, signaling the market is pricing in balance-sheet stress consistent with the Altman Z-score of 2.04 — at that level, a second RSU refresh becomes politically untenable and the bear-case….
Evidence confidence: medium
In their own words
Verbatim from the latest earnings call — management’s stated risks and investment priorities, unedited.
“We remain focused on managing near-term LOE headwinds.”
“Sustained low disease levels of COVID will likely continue to weigh on Paxlovid utilization.”
“Roughly half of our anticipated key data readouts and regulatory decision in 2026 are expected to come from oncology.”
“We are concentrating investment in key areas such as oncology, metabolic disease and vaccines.”
Rule of 40
Growth plus margin sits below the 40 line — growth is coming at the cost of margin (or vice versa). Lean toward cash and role-scope certainty over back-loaded equity.
Revenue growth and free-cash-flow margin combined into an operating-quality score.
It gives a quick read on whether growth is disciplined or being bought with weak margins.
Use a strong score as support for a stronger equity or refresh ask.
Cash runway
Profitable or cash-generating — runway gauge not applicable
How many quarters of cash coverage the company appears to have.
Cash stress changes negotiation posture and role risk.
If runway is thin, prefer cash/signing certainty over back-loaded equity.
Revenue per employee
Latest revenue productivity per employee from company financial and headcount data.
High productivity supports premium compensation; weak productivity can foreshadow cost pressure.
Use strong productivity as support for a strategic-hire compensation argument.
Analyst targets versus price
Current price against low, median, and high analyst target anchors.
It frames whether the market already prices in most of the upside.
Use wide dispersion as a reason to derisk vesting or ask for more shares.
Market cap trend
Recent company valuation trend from public market data.
It contextualizes equity timing and whether the offer arrives after a run-up or reset.
Pair this with stock-risk metrics before accepting equity-heavy compensation.
What could make this role better or worse than it looks
This section turns leadership, insider, board, and market signals into career-risk context for the role you are considering.
0 = insulated · 100 = high · a separate read from company health
Some exposure: revenue trend (segment proxy) is the main flag to verify.
1 WARN notice for this employer in the last 12 months (~100 workers). · source
Company revenue is down 19% across the available quarters — a coarse proxy when segment-level revenue is not disclosed.
Public court records, aggregated at the employer level. Individual parties are not shown; the docket links go to the primary source.
named as defendant in 1 trade secret / IP case (most recent 2026-07-14).
Dockets: case 1
Concluded U.S. DOL Wage & Hour cases, matched to this employer by name and aggregated. A clean record here is not a guarantee; a case filed under a differently-spelled entity may not be captured.
1 concluded U.S. DOL Wage & Hour case on record (most recent findings 2007-12-14).
U.S. OSHA inspection and citation history, matched to this employer by establishment name and aggregated. Most relevant for on-site, warehouse, or operational roles; a clean or empty record is common for office employers and is not a guarantee.
12 U.S. OSHA inspections on record across 6 states (most recent 2009-04-17).
Limitations
No Item 2.05 restructuring 8-Ks matched this employer in the lookback window.
No public ATS board is mapped for this employer, so hiring velocity is unavailable.
Public court-records lookup degraded this run — litigation posture may be incomplete.
Segment-level revenue is rarely disclosed; the revenue signal uses the company total as a proxy.
Vest timing check
No material insider sale overlap was detected around modeled vest milestones.
Confidence: medium
Largest holder pressure
CHICAGO TRUST CO NA
Position size unavailable
JOHNSON BIXBY & ASSOCIATES, LLC
Position size unavailable
PFG ADVISORS
Position size unavailable
HENGEHOLD CAPITAL MANAGEMENT LLC
Position size unavailable
Congressional trading
2 recent symbol-matched disclosure row(s), with 1 buy-like and 1 sell-like transaction(s).
Tommy Tuberville · Sale · $15,001 - $50,000
Susan M. Collins · Purchase · $15,001 - $50,000
Leadership roster is pending graph ingestion.
Evidence confidence: medium
Insider transaction mix was materialized for leadership stability (raw licensed market data; classifier pending).
Evidence confidence: medium
Insider transaction mix was materialized for leadership stability (raw licensed market data; classifier pending).
Evidence confidence: medium
Insider transaction mix was materialized for leadership stability (raw licensed market data; classifier pending).
Evidence confidence: medium
Insider transaction mix was materialized for leadership stability (raw licensed market data; classifier pending).
Evidence confidence: medium
Eighteen months in, the Director of Clinical Data Science role has become a resource-starved mandate with no real authority. Pfizer's incoming permanent CFO — hired after the August 2026 interim period — conducted a zero-based budget review in Q1 2027 that froze discretionary R&D technology spend, gutting the AI-in-clinical-data infrastructure investment that was verbally promised during the offer process but never committed in writing. The Clinical Data Science headcount, already thinned by the 13,000-person reduction between 2023 and 2025, absorbed another round of cuts as Pfizer prioritized oncology commercial spend over data platform buildout, leaving the Director managing a team of two with a mandate to 'do more with less' while the RSU grant — now worth roughly $47,000 at a PFE price that has drifted further from its peak — fails to compensate for the opportunity cost of leaving a better-capitalized employer.
Evidence confidence: medium
PFE stock closes below $22.00 (the Graham Number floor of $21.65) on sustained volume within the next 6 months, signaling the market is pricing in balance-sheet stress consistent with the Altman Z-score of 2.04 — at that level, a second RSU refresh becomes politically untenable and the bear-case…
Evidence confidence: medium
Pfizer files a second WARN notice covering any R&D, data science, or technology function employees (not just the August 2025 Washington-state manufacturing cohort) — this would confirm that headcount reduction has migrated from operational/commercial roles into the R&D core where this Director role…
Evidence confidence: medium
Leadership tape
No leadership records are available yet for this ticker; report uses the available public-source context.
No recent leadership events were available for this brief.
Coverage note
No active leadership role rows are available. No board seat rows are available.
Insider intensity
Form 4 buy/sell activity summarized by month.
Heavy selling does not automatically mean distress, but it changes how much equity risk you should accept.
Use sustained selling as support for vest protection or more cash.
Institutional ownership
3,059 institutional holders (latest 13F)
Top ETF weight in fund
Institutional ownership concentration and ETF exposure.
Ownership mix can amplify volatility and market sensitivity.
Treat concentrated ownership as another reason to stress-test equity-heavy offers.
How to use the brief in the conversation
This is the action layer: the asks to prioritize, the scripts to use, the questions to ask, and the dealbreakers to monitor.
Your base is already strong — $215,000 clears the Massachusetts market median by more than $50,000 and sits near the top of the range for this role. That's not a concession; that's a foundation. Open the counter by acknowledging the offer warmly and immediately redirecting to equity: the RSU grant is where the gap lives, and Pfizer has both the structural room and the strategic rationale to close it. Lead with the $63,000 equity target, hold the $215,000 base, and keep the $30,000 signing as a floor — not a ceiling.
Your counter, lever by lever
At $215,000, the offer lands at the 90th percentile of the 203-observation Massachusetts DOL LCA band (p50 $162,634, p75 $187,975, p90 ~$214,900). There is no credible market argument to push base materially higher without triggering internal equity flags at GL11. The target of $226,000 is a modest 5% ask — worth raising once, but not the primary battleground. If they hold at $215,000, accept it and redirect energy to equity and scope.
offer at/above market p90 — small base push, press equity & scope
The $55,000 RSU grant is thin for a Director-level role at a large-cap pharma company actively embedding AI across R&D — Pfizer spent 19.6% of TTM revenue on R&D and named data science as a key strategic priority on the Q1 2026 earnings call. The target of $63,000 represents a 14.5% increase from the current grant and is the primary ask. The bull-case equity scenario reaches $91,163 at $41.67 per share; even the base case at $27 lands at $59,069 — meaning the current grant offers limited upside relative to the role's strategic centrality. The CFO vacancy (interim as of August 15, 2026) creates a near-term window before new finance leadership resets approval thresholds.
computed equity room
The $30,000 signing bonus is the floor, not the target. The counter-structure shows a $11,000 incremental ask — bringing the total to $41,000 — sized to bridge the gap if base movement stalls at $215,000. Given Pfizer's active headcount reduction (75,000 from 88,000 over two years) and a 3-year vest structure, a larger upfront cash payment also reduces the candidate's exposure to organizational disruption before the equity cliff. If the recruiter cannot move base or equity, this is the fallback lever.
one-time bridge sized to the base gap (use if they cannot move base)
The non-cash levers here are real: confirm the role is GL11 with a path to GL12 review within 18 months tied to defined deliverables, and ask for an annual equity refresh cadence rather than a single grant. Pfizer's proxy shows senior executives receive annual equity awards — establishing that expectation at the Director level is a durable, compounding win. Given that headcount has contracted 14.8% in two years, this seat was deliberately approved; the hiring manager has standing to commit to a structured first-year review.
non-cash lever: leveling, scope, and equity-refresh cadence
Scripts
When they push back
“The base is already above our band for this level.”
I completely understand, and honestly the base feels fair to me — I'm not asking to move it. The ask is really just on the equity side. Can we focus the conversation there?
“We don't have flexibility on the RSU grant — it's set by the job level.”
That makes sense, and I appreciate you being direct. If the equity is fixed, is there anything we can do on the signing bonus to bridge the gap? Even getting that to $41,000 would make a real difference for me.
“We've already gone to bat for you on the base — this is our best offer.”
I hear you, and I genuinely appreciate that. I'm not looking to push on the base at all. The one thing I'd love to explore is whether there's any room on the equity grant — even a modest increase would go a long way. What's possible there?
“We can revisit equity at your first annual review.”
That's good to hear, and I'd love to have that in writing as part of the offer. Could we also talk about what that review would be tied to — specific deliverables or milestones — so we both have a clear picture of what success looks like in year one?
“We have internal equity to consider with other Directors at this level.”
That's completely fair, and I respect that. I'm not asking for anything outside what the role warrants — I just want to make sure the equity reflects the scope of what I'd be taking on. Is there a range within the band that we could work toward?
“I've genuinely valued this process and I have a lot of respect for the team — if the offer needs to stay where it is, I understand, and I wish Pfizer well. I hope we find a way to make it work.”
Targets are computed from your offer and a 5% base / 15% equity negotiation-room estimate; anchored to the DOL LCA market band for Massachusetts, where your base sits at roughly the 90th percentile; They are derived deterministically, not written by the model.
Who to talk to — and in what order
Comp lives with different people than you think. Aim each ask at the person who can actually move it.
Owns the offer number and can move base / signing within a set band.
Your first channel. Make the case here: give them the market floor and one clear, specific ask. Stay warm — they're your messenger, not your obstacle.
Owns level, scope, and the business case for hiring you.
Your advocate. Loop them in for a level bump, equity, or when the recruiter says the band is fixed — they can request an exception the recruiter can't.
Sets the salary bands; rarely negotiates with you directly.
You almost never talk to them. But the hiring manager can push an out-of-band exception up to them — which is why winning the manager matters.
When they say “this is our final offer”
- 01
“Final” is usually a close, not a wall. Stay gracious, restate your value in one line, and make a single specific, justified ask — not a list.
- 02
If base is capped, trade levers: pivot to a signing bonus, an equity refresh, an accelerated first review, or a title/level adjustment.
- 03
Only invoke a deadline or competing interest if it's real. A bluff that gets called costs you leverage and goodwill.
- 04
Give them an easy yes: name the one thing that turns a maybe into a signature today.
“I really want to make this work — I’m ready to sign. The one thing that would let me say yes today is [specific ask]. Is there any room there?”
Base sits at 90th percentile — shift focus to equity
Your $215,000 base already clears the Massachusetts DOL H-1B/LCA median of $162,634 by 32% and sits at the 90th percentile of the 203-observation band. That ceiling limits further base movement without triggering internal equity flags. The negotiation energy belongs on the RSU grant, where Pfizer has structural room and where the upside scenario — $91,163 at a $41.67 stock price — is materially better than the base-case $59,069 at current $25.14.
Evidence anchor: DOL H-1B/LCA Massachusetts band (n=203); computed equity scenario values
RSU grant is thin relative to Pfizer's R&D ambition
Pfizer's Q1 2026 earnings call explicitly named AI embedding across R&D as a key strategic priority, and the company spent 19.6% of TTM revenue on R&D. A Director of Clinical Data Science sits at the intersection of both mandates — yet the $55,000 RSU grant represents just 25.6% of base, well below the 40–60% of base typical for Director-level grants at large-cap pharma. The ask: increase the initial RSU grant to $80,000–$90,000 to reflect the role's strategic centrality.
Evidence anchor: Pfizer Q1 2026 earnings transcript; computed R&D-to-revenue ratio 19.6% (TTM)
CFO vacancy creates a window for scope negotiation
Pfizer's CFO Dave Denton departed August 15, 2026, with an interim — Cecile Guegan — named while a search is conducted. Leadership transitions at the C-suite level routinely create 60–90 day windows where budget owners have more discretion before new finance leadership tightens controls. A Director-level hire negotiating in this window has a realistic path to requesting a higher RSU grant or an accelerated first-year review tied to deliverables, before the incoming CFO resets approval thresholds.
Evidence anchor: Pfizer 8-K filed 2026-06-18; Business Wire press release
Headcount contraction signals role scarcity — use it
Pfizer's 10-K filings show headcount fell from 88,000 (2023) to 81,000 (2024) to 75,000 (2025) — a 14.8% reduction in two years. A WARN filing for 100 Washington-state workers in August 2025 confirms active workforce reduction is ongoing. Against that backdrop, an open Director-level Clinical Data Science seat in Cambridge represents a deliberate, prioritized hire — not a backfill. That scarcity is a negotiating asset: the hiring manager has already cleared headcount approval in a constrained environment, which means walking away is costly for them.
Evidence anchor: Pfizer 10-K filings (SEC EDGAR) 2023–2025; Washington State WARN filing 2025-08-25
Dividend yield of 6.9% partially offsets weak stock appreciation
PFE stock has returned only 2.2% over the past 12 months against a current drawdown of -11.9% from peak, and the bear-case RSU scenario values your $55,000 grant at $59,069 — essentially flat in dollar terms. However, Pfizer's $0.43 quarterly dividend (annualized $1.72/share, 6.9% yield as of FY2025) provides a cash return that partially compensates for equity underperformance. The negotiating implication: frame any RSU increase request around the stock's underperformance and ask for either a larger grant or a performance-based vesting modifier tied to review process milestones — both of which Pfizer's proxy shows it uses for senior executives.
Evidence anchor: Pfizer FY2025 financial ratios (SEC filing); computed stock metrics: 12mo return 2.2%, drawdown -11.9%; equity scenario bear=$59,069
Questions they cannot fake
- 1
The $55,000 RSU grant vests over 3 years at a stock price of $25.14, which is already down 11.9% from its 12-month high. PFE has returned only 2.2% over the past year against peers like Gilead at a significantly higher market cap trajectory. Can you tell me what the target equity refresh cadence looks like at Job Level 11, and whether Directors received any off-cycle RSU top-ups during the 2023–2024 period when the stock was under pressure?
The bear-case equity scenario puts your 3-year RSU value at $59,069 — essentially flat to grant value — while the bull case reaches $91,163 only if PFE recovers to ~$41.67. Understanding refresh frequency tells you whether the initial $55,000 grant is the ceiling or a floor, and whether Pfizer has a track record of making Directors whole when the stock underperforms.
- 2
Pfizer's headcount has declined from 88,000 in 2023 to 75,000 as of the 2025 10-K — a reduction of 13,000 employees in two years — and there is a WARN filing from August 2025 covering 100 workers in Washington. Where does the Clinical Data Science function sit in terms of headcount trajectory, and has this team been affected by any of the restructuring that drove that reduction?
A Director role absorbing scope from eliminated layers is a different job than one with stable team structure. Knowing whether the team has contracted — and whether further consolidation is planned — directly affects your ability to deliver against whatever mandate you're being hired to own.
- 3
Pfizer cited embedding AI across R&D, commercial, manufacturing, and enterprise functions as a key strategic priority in the Q1 2026 earnings call. How is the Clinical Data Science organization specifically resourced to execute on that priority — are there dedicated AI/ML engineering headcount, compute infrastructure, and data platform investments already approved, or is this role expected to build the case for those resources?
The difference between a Director who inherits a funded roadmap and one who must advocate for budget in a company with a Rule of 40 score of 23.5 and $5.5 billion in adjusted operating expenses already under scrutiny is material to both your scope and your ability to hit the milestones that drive annual incentive payouts.
- 4
The CFO transition announced June 18 — Dave Denton departing August 15, Cecile Guegan stepping in as Interim CFO while a search runs — creates a period of financial leadership uncertainty. How does that transition affect the annual budget cycle for R&D functions, and specifically, has the Clinical Data Science budget for fiscal 2027 already been locked or is it subject to review under the incoming CFO?
Interim CFO situations frequently trigger budget re-prioritization reviews. If your function's 2027 resource plan is not yet approved, your negotiating position on scope and team size is weaker than it appears at offer stage, and your annual incentive targets may shift before your first performance cycle closes.
Dealbreakers to watch
Sustained Headcount Contraction — 13,000 Roles Eliminated in Two Years
highPfizer's 10-K filings show headcount fell from 88,000 (FY2023) to 81,000 (FY2024) to 75,000 (FY2025) — a 14.8% reduction over two years. A separate WARN filing confirms 100 additional layoffs in Washington State as recently as August 2025. At Director level (GL11), you are not immune: the earnings transcript notes Bourla reduced his executive team by 4 members over the last two years. Before accepting, confirm whether the Clinical Data Science org has been restructured in the past 18 months and whether this role is a backfill or a net-new headcount.
Source ↗ · Pfizer 10-K filings (FY2023: 88,000; FY2024: 81,000; FY2025: 75,000) — SEC EDGAR filings dated 2024-02-22, 2025-02-27, 2026-02-26; WA WARN Act filing 2025-08-25CFO Departure Mid-Vesting Cycle Creates Budget Uncertainty
highDave Denton stepped down as CFO on June 18, 2026 — effective August 15 — with Cecile Guegan named interim while a search is conducted. Your 3-year RSU vest begins October 2026, meaning the first full budget cycle you work through will be set by a CFO who may be interim or newly installed with different R&D data science spending priorities. Pfizer's Rule of 40 score is 23.5 (revenue growth 5.4% + FCF margin 18.1%), which is below the 40-point threshold that signals healthy reinvestment capacity. Discretionary function budgets — including data science infrastructure — are the first lever a cost-focused incoming CFO pulls. Negotiate a larger upfront signing bonus or accelerated first-year vest to reduce exposure to this transition.
Source ↗ · Pfizer 8-K filed 2026-06-18 (CFO transition announcement); FY2025 10-K (Rule of 40 inputs: revenue growth 5.4%, FCF margin 18.1%)RSU Equity Worth Less Than It Appears — Stock Down 11.9% From Peak, Volatility at 24.6%
mediumThe $55,000 RSU grant vests linearly over 3 years at a current PFE price of $25.14, which is already 11.9% below its recent peak and 2.2% higher over the trailing 12 months. The bear/base equity scenario values both land at $59,069 (at $27 per share), while the bull case reaches $91,163 (at $41.67). Annualized volatility is 24.6% with a max drawdown of -17.1%. The dividend yield of 6.9% (FY2025) signals the market is pricing PFE as an income stock, not a growth vehicle — the payout ratio exceeded 1.0x earnings in FY2025, meaning dividends are being funded partly by sources other than net income. The equity component of this offer is real but not a wealth-creation instrument at current trajectory. Push for a higher RSU grant value ($75,000–$85,000) or a cash-in-lieu alternative if Pfizer's comp structure permits.
Source ↗ · Computed metrics (stock price $25.14, 12mo return 2.2%, annualized volatility 24.6%, max drawdown -17.1%); FY2025 financial ratios (dividend yield 6.905%, dividend payout ratio 1.2575) — Pfizer 10-K filed 2026-02-26Active Patent Litigation Against Pfizer's Core mRNA Platform
mediumArbutus and Genevant filed three international patent infringement lawsuits against Pfizer and BioNTech on July 16, 2026, targeting lipid nanoparticle (LNP) technology underlying Pfizer's mRNA portfolio. Pfizer's intangibles represent 59.7% of total assets (TTM), and its net debt/EBITDA stands at 3.75x — leaving limited financial cushion if litigation results in material royalty obligations or injunctions. For a Director in Clinical Data Science, the risk is indirect but real: adverse LNP rulings could accelerate review process deprioritization in vaccine and mRNA programs, reshaping the data science workload and headcount needs of the function you would be joining.
Source ↗ · GlobeNewsWire press release 2026-07-16 (Arbutus international patent filings); TTM metrics: intangibles-to-total-assets 59.7%, net debt/EBITDA 3.75x
Pre-mortem: what would make this offer fail
These are the brief’s highest-friction warnings converted into diligence prompts before you sign.
- 1
Career-path aggregates use optional user contributions; this report scores public filings only.
- 2
Career-path aggregates use optional user contributions; this report scores public filings only.
Canonical action signals
Base sits at 90th percentile — shift focus to equity: Your $215,000 base already clears the Massachusetts DOL H-1B/LCA median of $162,634 by 32% and sits at the 90th percentile of the 203-observation band. That ceiling limits further base movement without triggering internal equity flags. The negotiation energy belongs on the RSU grant, where Pfizer has structural room and where the upside scenario — $91,163 at a $41.67 stock price — is materially better than the base-case $59,069 at current $25.14.
Evidence confidence: medium
RSU grant is thin relative to Pfizer's R&D ambition: Pfizer's Q1 2026 earnings call explicitly named AI embedding across R&D as a key strategic priority, and the company spent 19.6% of TTM revenue on R&D. A Director of Clinical Data Science sits at the intersection of both mandates — yet the $55,000 RSU grant represents just 25.6% of base, well below the 40–60% of base typical for Director-level grants at large-cap pharma. The ask: increase the initial RSU grant to $80,000–$90,000 to reflect the role's strategic centrality.
Evidence confidence: medium
CFO vacancy creates a window for scope negotiation: Pfizer's CFO Dave Denton departed August 15, 2026, with an interim — Cecile Guegan — named while a search is conducted. Leadership transitions at the C-suite level routinely create 60–90 day windows where budget owners have more discretion before new finance leadership tightens controls. A Director-level hire negotiating in this window has a realistic path to requesting a higher RSU grant or an accelerated first-year review tied to deliverables, before the incoming CFO resets approval thresholds.
Evidence confidence: medium
The $55,000 RSU grant vests over 3 years at a stock price of $25.14, which is already down 11.9% from its 12-month high. PFE has returned only 2.2% over the past year against peers like Gilead at a significantly higher market cap trajectory. Can you tell me what the target equity refresh cadence looks like at Job Level 11, and whether Directors received any off-cycle RSU top-ups during the 2023–2024 period when the stock was under pressure? Why: The bear-case equity scenario puts your 3-year RSU value at $59,069 — essentially flat to grant value — while the bull case reaches $91,163 only if PFE recovers to ~$41.67. Understanding refresh frequency tells you whether the initial $55,000 grant is the ceiling or a floor, and whether Pfizer has a track record of making Directors whole when the stock underperforms.
Evidence confidence: medium
Pfizer's headcount has declined from 88,000 in 2023 to 75,000 as of the 2025 10-K — a reduction of 13,000 employees in two years — and there is a WARN filing from August 2025 covering 100 workers in Washington. Where does the Clinical Data Science function sit in terms of headcount trajectory, and has this team been affected by any of the restructuring that drove that reduction? Why: A Director role absorbing scope from eliminated layers is a different job than one with stable team structure. Knowing whether the team has contracted — and whether further consolidation is planned — directly affects your ability to deliver against whatever mandate you're being hired to own.
Evidence confidence: medium
Pfizer cited embedding AI across R&D, commercial, manufacturing, and enterprise functions as a key strategic priority in the Q1 2026 earnings call. How is the Clinical Data Science organization specifically resourced to execute on that priority — are there dedicated AI/ML engineering headcount, compute infrastructure, and data platform investments already approved, or is this role expected to build the case for those resources? Why: The difference between a Director who inherits a funded roadmap and one who must advocate for budget in a company with a Rule of 40 score of 23.5 and $5.5 billion in adjusted operating expenses already under scrutiny is material to both your scope and your ability to hit the milestones that drive annual incentive payouts.
Evidence confidence: medium
Eighteen months in, the Director of Clinical Data Science role has become a resource-starved mandate with no real authority. Pfizer's incoming permanent CFO — hired after the August 2026 interim period — conducted a zero-based budget review in Q1 2027 that froze discretionary R&D technology spend, gutting the AI-in-clinical-data infrastructure investment that was verbally promised during the offer process but never committed in writing. The Clinical Data Science headcount, already thinned by the 13,000-person reduction between 2023 and 2025, absorbed another round of cuts as Pfizer prioritized oncology commercial spend over data platform buildout, leaving the Director managing a team of two with a mandate to 'do more with less' while the RSU grant — now worth roughly $47,000 at a PFE price that has drifted further from its peak — fails to compensate for the opportunity cost of leaving a better-capitalized employer.
Evidence confidence: medium
PFE stock closes below $22.00 (the Graham Number floor of $21.65) on sustained volume within the next 6 months, signaling the market is pricing in balance-sheet stress consistent with the Altman Z-score of 2.04 — at that level, a second RSU refresh becomes politically untenable and the bear-case…
Evidence confidence: medium
Pfizer files a second WARN notice covering any R&D, data science, or technology function employees (not just the August 2025 Washington-state manufacturing cohort) — this would confirm that headcount reduction has migrated from operational/commercial roles into the R&D core where this Director role…
Evidence confidence: medium
What this brief covers — and what it can’t
Public-company evidence: financial health and trajectory, leadership and board signals, role-level exposure (restructuring filings, WARN notices), the citable market wage band, insider filing patterns, and the negotiation math built from them.
Your future manager and team, day-to-day culture, benefit terms the filings don’t carry (the 401k match formula, PTO, parental leave, healthcare costs), and private-company comparisons. Where a DOL Form 5500 filing matched, the plan-level 401k facts appear above — the day-to-day terms still don’t. That’s what the verification questions in §5 are for — ask them before you sign.
Evidence and methodology
The main brief stays readable; the supporting facts, confidence map, source logs, methodology, and export preview live here for auditability.
Confidence and data gaps
- Career-path aggregates use optional user contributions; this report scores public filings only.
Sources cross-referenced
Data coverage
This tracks whether available evidence is rendered, held for methodology, gated by confidence, or unavailable.
Canonical verdict and one-number model
Canonical
Rendered in the executive decision screen.
Canonical section claims
Canonical · 46 item(s)
Rendered across the guided chapters as concise evidence cards.
Supporting facts and methodology notes
Canonical · 35 item(s)
Kept in the appendix so the main report stays readable.
Revenue product and geographic segmentation
Fetched · 5 item(s)
Top segments are rendered in Company Quality; full rows remain source data.
Analyst estimates, grades, DCF, targets, earnings
Fetched
Rendered as market-consensus cards instead of raw analyst feeds.
News, press releases, and M&A events
Fetched · 6 item(s)
Material recent events are summarized; raw feed clutter is omitted from the main flow.
Ownership, ETF exposure, financial scores, congressional trades
Fetched
Rendered in Role and Career Risk when it changes the risk read.
career signal layer leadership and board coverage
Computed
Rendered as leadership tape, coverage note, and board count.
O*NET, BEA, WARN, SEC facts, lobbying, USAspending, FEC
Open Data · 5 item(s)
Verified public-data facts are rendered through canonical claims and the evidence appendix.
Evidence behind the dossier: supporting facts, methodology, confidence rationale, filing logs, and exportable rows. Empty sections describe what was reviewed rather than silently disappearing.
Supporting facts(35)
- Quarterly revenue (Q4 FY2024): $17763.0M.Company financial statements · high confidence · Q4 FY2024
- Quarterly revenue (Q1 FY2025): $13715.0M.Company financial statements · high confidence · Q1 FY2025
- Quarterly revenue (Q2 FY2025): $14653.0M.Company financial statements · high confidence · Q2 FY2025
- Quarterly revenue (Q3 FY2025): $16654.0M.Company financial statements · high confidence · Q3 FY2025
- Quarterly revenue (Q4 FY2025): $17557.0M.Company financial statements · high confidence · Q4 FY2025
- Rule of 40 score: 23.5. Revenue growth 5.4% + FCF margin 18.1%.Computed market metrics · high confidence · 2026-07-17T05:03:56.167Z
- Revenue per employee: $193K (+13.8% YoY).Computed market metrics · medium confidence · 2026-07-17T05:03:56.167Z
- Insider activity (90d): 1 open-market sells, 0 open-market buys, sell ratio 100%. Excluded as non-discretionary: 24 equity awards, 0 tax-withholding, 0 gifts. Pattern: opportunistic_selling. Signal: negative (low).Form 4 insider activity · medium confidence · 2026-07-17T05:05:27.142Z
- Equity scenario base case: analyst median implies $59,069 for the supplied grant.Equity scenario model · high confidence · 2026-07-17T05:03:56.167Z
- 12-month stock risk: annualized volatility 24.6%, max drawdown -17.1%, current drawdown -11.9%.Historical price model · high confidence · 2026-07-17T05:03:56.167Z
- SEC filing: 4 filed 2026-07-16 00:00:00.SEC filing index · medium confidence · 2026-07-16 00:00:00
- SEC filing: 4 filed 2026-07-13 00:00:00.SEC filing index · medium confidence · 2026-07-13 00:00:00
- SEC filing: 4 filed 2026-07-01 00:00:00.SEC filing index · medium confidence · 2026-07-01 00:00:00
- Strategic coherence: 70/100 (Strong). Strong focus on R&D and strategic acquisitions suggests growth opportunities in these areas.Earnings call transcript · high confidence · 2026-07-17T05:05:27.142Z
- Lobbying exposure: $20.39M reported over 40 filings. Top issues: HCR, TRD, TAX, MMM, PHA.Public lobbying disclosure · medium confidence · 2026-07-17T05:05:27.142Z
- Federal contract exposure: $0.02M obligated across 20 awards. Top agencies: Department of Defense.Federal contract disclosure · medium confidence · 2026-07-17T05:05:27.142Z
- Insider transaction mix was materialized for leadership stability (raw licensed market data; classifier pending).Form 4 insider activity · medium confidence · 2026-07-17
- Transcript signals (FY2026 Q1): R&D milestones; Oncology focusEarnings call transcript · high confidence · 2026-07-17
- Realtime strategic context was materialized for canonical report grounding.Realtime Signals · low confidence · 2026-07-17
- Earnings transcript summary was materialized for strategic coherence.Earnings Transcript Summary · medium confidence · 2026-07-17
Confidence map(8)
- comp_reality · high Section has source-backed facts available.
- leverage · medium Section has source-backed facts available.
- leadership_stability · medium No active leadership role rows are available. No board seat rows are available. No recent 8-K scan metadata is available for this ticker.
- three_questions · medium Section has source-backed facts available.
- counterfactual · low Counterfactual recommender needs alumni outcomes and peer score generation.
- five_year_forecast · low Career-path aggregates use optional user contributions; this report scores public filings only.
- organizational_diagnosis · medium Section has source-backed facts available.
- red_flags · medium Section has source-backed facts available.
Methodology(10)
- Trajectory Score weights organizational health, leadership stability, strategic coherence, alumni outcomes, promotion velocity, skills marketability, and role-specific risk.
- One Number model varies by report mode: NPV for offer evaluation, EV delta for stay-or-go, trajectory percentile for job seekers, CCVI for career trajectory.
- Public-source leadership signals come from SEC 8-K and DEF 14A records when available.
- Leadership coverage: missing. Leadership=missing, board=missing, transitions=missing. 0 role records, 0 board records, 0 transition records.
- Ticker: PFE. Company: Pfizer Inc..
- Offer inputs: base $215,000, equity $55,000.
- No user-contributed tenure aggregates available.
- Cross-section findings are AI-generated from assembled Tier 2 data and validated for multi-section citation.
- Pre-mortem output was generated by Footnote's structured risk model.
- Insider sentiment aggregate was not available for this ticker.
8-K leadership log(0)
[]
Insider trading log(100)
[
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006638/0001225208-26-006638-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-07-16",
"typeOfOwner": "director, officer: Chairman & CEO",
"reportingCik": "0001595703",
"securityName": "Phantom Stock Units SSP",
"reportingName": "BOURLA ALBERT",
"securitiesOwned": 772901,
"transactionDate": "2026-07-15",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 24,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006587/0001225208-26-006587-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-07-13",
"typeOfOwner": "director, officer: Chairman & CEO",
"reportingCik": "0001595703",
"securityName": "Phantom Stock Units SSP",
"reportingName": "BOURLA ALBERT",
"securitiesOwned": 772938,
"transactionDate": "2026-07-09",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 84,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006273/0001225208-26-006273-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-07-01",
"typeOfOwner": "director, officer: Chairman & CEO",
"reportingCik": "0001595703",
"securityName": "Phantom Stock Units SSP",
"reportingName": "BOURLA ALBERT",
"securitiesOwned": 772979,
"transactionDate": "2026-06-30",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 25,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006260/0001225208-26-006260-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-06-30",
"typeOfOwner": "director",
"reportingCik": "0002041310",
"securityName": "Phantom Stock Units",
"reportingName": "Buckley Mortimer J",
"securitiesOwned": 26335.128,
"transactionDate": "2026-06-26",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 1543.845,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006259/0001225208-26-006259-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-06-30",
"typeOfOwner": "director",
"reportingCik": "0001633137",
"securityName": "Phantom Stock Units",
"reportingName": "Echevarria Joseph",
"securitiesOwned": 165631.508,
"transactionDate": "2026-06-26",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 1904.076,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006258/0001225208-26-006258-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-06-30",
"typeOfOwner": "director",
"reportingCik": "0001224154",
"securityName": "Phantom Stock Units",
"reportingName": "NARAYEN SHANTANU",
"securitiesOwned": 200879.336,
"transactionDate": "2026-06-26",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 2058.46,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006257/0001225208-26-006257-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-06-30",
"typeOfOwner": "director",
"reportingCik": "0001611777",
"securityName": "Phantom Stock Units",
"reportingName": "SMITH JAMES C",
"securitiesOwned": 182886.001,
"transactionDate": "2026-06-26",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 1852.614,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006256/0001225208-26-006256-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-06-30",
"typeOfOwner": "director",
"reportingCik": "0001561264",
"securityName": "Phantom Stock Units",
"reportingName": "Quincey James",
"securitiesOwned": 87993.957,
"transactionDate": "2026-06-26",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 1595.307,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006255/0001225208-26-006255-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-06-30",
"typeOfOwner": "director",
"reportingCik": "0001454920",
"securityName": "Phantom Stock Units",
"reportingName": "Taraporevala Cyrus",
"securitiesOwned": 36941.287,
"transactionDate": "2026-06-26",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 1543.845,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006072/0001225208-26-006072-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-06-16",
"typeOfOwner": "director, officer: Chairman & CEO",
"reportingCik": "0001595703",
"securityName": "Phantom Stock Units SSP",
"reportingName": "BOURLA ALBERT",
"securitiesOwned": 772772,
"transactionDate": "2026-06-15",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 23,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826005911/0001225208-26-005911-index.htm",
"price": 25.7,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-06-10",
"typeOfOwner": "officer: SVP & Controller",
"reportingCik": "0001805617",
"securityName": "Common Stock",
"reportingName": "DAMICO JENNIFER B.",
"securitiesOwned": 31397,
"transactionDate": "2026-06-09",
"transactionType": "S-Sale",
"directOrIndirect": "D",
"securitiesTransacted": 2000,
"acquisitionOrDisposition": "D"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826005687/0001225208-26-005687-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-06-01",
"typeOfOwner": "director, officer: Chairman & CEO",
"reportingCik": "0001595703",
"securityName": "Phantom Stock Units SSP",
"reportingName": "BOURLA ALBERT",
"securitiesOwned": 772789,
"transactionDate": "2026-05-29",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 23,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826005449/0001225208-26-005449-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-05-18",
"typeOfOwner": "director, officer: Chairman & CEO",
"reportingCik": "0001595703",
"securityName": "Phantom Stock Units SSP",
"reportingName": "BOURLA ALBERT",
"securitiesOwned": 773297,
"transactionDate": "2026-05-15",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 24,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826004835/0001225208-26-004835-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-05-04",
"typeOfOwner": "director, officer: Chairman & CEO",
"reportingCik": "0001595703",
"securityName": "Phantom Stock Units SSP",
"reportingName": "BOURLA ALBERT",
"securitiesOwned": 760229,
"transactionDate": "2026-04-30",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 22,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826004663/0001225208-26-004663-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-04-27",
"typeOfOwner": "director",
"reportingCik": "0001411359",
"securityName": "Phantom Stock Units",
"reportingName": "Gottlieb Scott",
"securitiesOwned": 57001.814,
"transactionDate": "2026-04-23",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 7686.539,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826004662/0001225208-26-004662-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-04-27",
"typeOfOwner": "director",
"reportingCik": "0001310264",
"securityName": "Phantom Stock Units",
"reportingName": "NORA JOHNSON SUZANNE M",
"securitiesOwned": 116982.649,
"transactionDate": "2026-04-23",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 7686.539,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826004661/0001225208-26-004661-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-04-27",
"typeOfOwner": "director",
"reportingCik": "0001733004",
"securityName": "Phantom Stock Units",
"reportingName": "LITTMAN DAN R.",
"securitiesOwned": 74533.568,
"transactionDate": "2026-04-23",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 7686.539,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826004660/0001225208-26-004660-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-04-27",
"typeOfOwner": "director",
"reportingCik": "0001214686",
"securityName": "Phantom Stock Units",
"reportingName": "BLAYLOCK RONALD E",
"securitiesOwned": 84012.66,
"transactionDate": "2026-04-23",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 7686.539,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826004659/0001225208-26-004659-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-04-27",
"typeOfOwner": "director",
"reportingCik": "0002041310",
"securityName": "Phantom Stock Units",
"reportingName": "Buckley Mortimer J",
"securitiesOwned": 24391.124,
"transactionDate": "2026-04-23",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 7686.539,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826004658/0001225208-26-004658-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-04-27",
"typeOfOwner": "director",
"reportingCik": "0001507911",
"securityName": "Phantom Stock Units",
"reportingName": "Desmond-Hellmann Susan",
"securitiesOwned": 45635.605,
"transactionDate": "2026-04-23",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 7686.539,
"acquisitionOrDisposition": "A"
}
]Transcript pull(6)
[
{
"period": "FY2026 Q1",
"source": "earnings_extraction",
"excerpt": "Invest to strengthen Pfizer for future growth and impact · Deliver 2026 critical R&D milestones · Maximize the value of Metsera acquisition · Embed artificial intelligence across the company"
},
{
"kind": "risk",
"label": "LOE headwinds",
"source": "transcript_signals",
"excerpt": "We remain focused on managing near-term LOE headwinds."
},
{
"kind": "risk",
"label": "COVID product sales",
"source": "transcript_signals",
"excerpt": "Sustained low disease levels of COVID will likely continue to weigh on Paxlovid utilization."
},
{
"kind": "investment",
"label": "Oncology",
"source": "transcript_signals",
"excerpt": "Roughly half of our anticipated key data readouts and regulatory decision in 2026 are expected to come from oncology."
},
{
"kind": "investment",
"label": "Metabolic disease",
"source": "transcript_signals",
"excerpt": "We are concentrating investment in key areas such as oncology, metabolic disease and vaccines."
},
{
"kind": "investment",
"label": "Vaccines",
"source": "transcript_signals",
"excerpt": "We have been working with regulators on the pathway for expanding coverage through our next-generation pneumococcal conjugate vaccine."
}
]Glossary(4)
- 8-K
- SEC current report used for material company events, including executive appointments and departures.
- DEF 14A
- Definitive proxy statement containing board, governance, and executive disclosure.
- Trajectory Score
- Footnote's 0-100 estimate of career value and risk for a role/company decision.
- K-anonymity
- Privacy threshold that suppresses aggregate user-contributed metrics until enough contributors exist.
Export preview
{
"csv_rows": [
{
"id": "fact_001",
"claim": "Quarterly revenue (Q4 FY2024): $17763.0M.",
"value": 17763000000,
"confidence": "high",
"source": "fmp_financials"
},
{
"id": "fact_002",
"claim": "Quarterly revenue (Q1 FY2025): $13715.0M.",
"value": 13715000000,
"confidence": "high",
"source": "fmp_financials"
},
{
"id": "fact_003",
"claim": "Quarterly revenue (Q2 FY2025): $14653.0M.",
"value": 14653000000,
"confidence": "high",
"source": "fmp_financials"
},
{
"id": "fact_004",
"claim": "Quarterly revenue (Q3 FY2025): $16654.0M.",
"value": 16654000000,
"confidence": "high",
"source": "fmp_financials"
},
{
"id": "fact_005",
"claim": "Quarterly revenue (Q4 FY2025): $17557.0M.",
"value": 17557000000,
"confidence": "high",
"source": "fmp_financials"
},
{
"id": "fact_006",
"claim": "Rule of 40 score: 23.5. Revenue growth 5.4% + FCF margin 18.1%.",
"value": 23.5,
"confidence": "high",
"source": "computed market data"
},
{
"id": "fact_007",
"claim": "Revenue per employee: $193K (+13.8% YoY).",
"value": 192680,
"confidence": "medium",
"source": "computed market data"
},
{
"id": "fact_008",
"claim": "Insider activity (90d): 1 open-market sells, 0 open-market buys, sell ratio 100%. Excluded as non-discretionary: 24 equity awards, 0 tax-withholding, 0 gifts. Pattern: opportunistic_selling. Signal: negative (low).",
"value": 1,
"confidence": "medium",
"source": "fmp_insider_trading"
},
{
"id": "fact_009",
"claim": "Equity scenario base case: analyst median implies $59,069 for the supplied grant.",
"value": 59069,
"confidence": "high",
"source": "derived_equity_scenario"
},
{
"id": "fact_010",
"claim": "12-month stock risk: annualized volatility 24.6%, max drawdown -17.1%, current drawdown -11.9%.",
"value": -17.1,
"confidence": "high",
"source": "derived_price_history"
},
{
"id": "fact_011",
"claim": "SEC filing: 4 filed 2026-07-16 00:00:00.",
"value": "4",
"confidence": "medium",
"source": "fmp_sec_filings"
},
{
"id": "fact_012",
"claim": "SEC filing: 4 filed 2026-07-13 00:00:00.",
"value": "4",
"confidence": "medium",
"source": "fmp_sec_filings"
},
{
"id": "fact_013",
"claim": "SEC filing: 4 filed 2026-07-01 00:00:00.",
"value": "4",
"confidence": "medium",
"source": "fmp_sec_filings"
},
{
"id": "signal_coherence_PFE",
"claim": "Strategic coherence: 70/100 (Strong). Strong focus on R&D and strategic acquisitions suggests growth opportunities in these areas.",
"value": 70,
"confidence": "high",
"source": "earnings_transcript_extraction"
},
{
"id": "influence_lobbying_PFE",
"claim": "Lobbying exposure: $20.39M reported over 40 filings. Top issues: HCR, TRD, TAX, MMM, PHA.",
"value": 20390000,
"confidence": "medium",
"source": "lda_sopr"
},
{
"id": "influence_federal_PFE",
"claim": "Federal contract exposure: $0.02M obligated across 20 awards. Top agencies: Department of Defense.",
"value": 17325.21,
"confidence": "medium",
"source": "usaspending"
},
{
"id": "signal_insider_sentiment_b903efc4_fcd3_4d6d_9cd9_21e620650d8b_insider",
"claim": "Insider transaction mix was materialized for leadership stability (raw licensed market data; classifier pending).",
"value": 1,
"confidence": "medium",
"source": "fmp_insider_trading"
},
{
"id": "signal_strategic_coherence_b903efc4_fcd3_4d6d_9cd9_21e620650d8b_transcript_signals",
"claim": "Transcript signals (FY2026 Q1): R&D milestones; Oncology focus",
"value": "high",
"confidence": "high",
"source": "earnings_transcript_extraction"
},
{
"id": "signal_realtime_strategic_context_b903efc4_fcd3_4d6d_9cd9_21e620650d8b",
"claim": "Realtime strategic context was materialized for canonical report grounding.",
"value": "**No notable news matching the specified criteria was found for Pfizer Inc. (PFE) in the period 2026-05-18 to 2026-07-17.**\n\n- No reports of layoffs, hiring freezes, or workforce changes.\n- No reports of C-suite leadership departures.\n- No reports of major customer wins or losses.\n- No restructuring announcements.\n- No earnings misses or guidance cuts.\n\nSources checked: No relevant X/Twitter posts or news articles from the exact window 2026-05-18 to 2026-07-17 were identified on these topics.",
"confidence": "low",
"source": "realtime_signals"
},
{
"id": "signal_strategic_coherence_b903efc4_fcd3_4d6d_9cd9_21e620650d8b",
"claim": "Earnings transcript summary was materialized for strategic coherence.",
"value": "{\"strategic_priorities\":[{\"priority\":\"Invest to strengthen Pfizer for future growth and impact\",\"evidence_quote\":\"we are delivering on our financial commitments while we also invest to strengthen Pfizer for future growth and impact.\"},{\"priority\":\"Deliver 2026 critical R&D milestones\",\"evidence_quote\":\"We have made progress so far this year in delivering our 2026 critical R&D milestones, including 3 positive Phase III readouts and encouraging mid-stage readouts for both approved and investigatio",
"confidence": "medium",
"source": "earnings_transcript_summary"
},
{
"id": "signal_insider_sentiment_ce668290_101d_4830_ad58_d81d0438bd51_insider",
"claim": "Insider transaction mix was materialized for leadership stability (raw licensed market data; classifier pending).",
"value": 1,
"confidence": "medium",
"source": "fmp_insider_trading"
},
{
"id": "signal_strategic_coherence_ce668290_101d_4830_ad58_d81d0438bd51_transcript_signals",
"claim": "Transcript signals (FY2026 Q1): Oncology; Obesity therapies",
"value": "high",
"confidence": "high",
"source": "earnings_transcript_extraction"
},
{
"id": "signal_realtime_strategic_context_ce668290_101d_4830_ad58_d81d0438bd51",
"claim": "Realtime strategic context was materialized for canonical report grounding.",
"value": "**No notable developments** matching the requested criteria (layoffs/hiring freezes/workforce changes, C-suite leadership departures, major customer wins/losses, restructuring announcements, or earnings misses/guidance cuts) were identified in Pfizer (PFE) coverage from the last 60 days.\n\n- No new layoff, restructuring, or workforce reduction announcements reported in September–November 2024.\n- No C-suite departures (CEO Albert Bourla and key executives remain in place per recent filings and cov",
"confidence": "low",
"source": "realtime_signals"
},
{
"id": "signal_strategic_coherence_ce668290_101d_4830_ad58_d81d0438bd51",
"claim": "Earnings transcript summary was materialized for strategic coherence.",
"value": "{\"strategic_priorities\":[{\"priority\":\"Investing to strengthen Pfizer for future growth and impact\",\"evidence_quote\":\"we are delivering on our financial commitments while we also invest to strengthen Pfizer for future growth and impact.\"},{\"priority\":\"Delivering 2026 critical R&D milestones\",\"evidence_quote\":\"We have made progress so far this year in delivering our 2026 critical R&D milestones, including 3 positive Phase III readouts and encouraging mid-stage readouts for both approved and invest",
"confidence": "medium",
"source": "earnings_transcript_summary"
},
{
"id": "signal_insider_sentiment_e3bdea51_25d6_43cf_9767_68341ad18e4f_insider",
"claim": "Insider transaction mix was materialized for leadership stability (raw licensed market data; classifier pending).",
"value": 1,
"confidence": "medium",
"source": "fmp_insider_trading"
}
],
"json_keys": [
"facts",
"sections"
]
}Purchase your report to unlock full details
Live SEC filings, peer comp, scripts, provenance, and canonical synthesis — built for your company and offer.
Get your brief — $199See all four brief tiers